Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.

Autor: Chami B; Établissement Français du Sang Île-de-France, Paris, France., Okuda M; Toho University Medical Center Omori Hospital, Tokyo, Japan., Moayeri M; Transfusion Service, University of California San Francisco, San Francisco, California, USA., Pirenne F; Établissement Français du Sang Île-de-France, Paris, France., Hidaka Y; Toho University Medical Center Omori Hospital, Tokyo, Japan., Nambiar A; Transfusion Service, University of California San Francisco, San Francisco, California, USA., Song Z; Sanofi, Global Oncology, Cambridge, Massachusetts, USA., Bedel O; Sanofi, Global Oncology, Cambridge, Massachusetts, USA.; Worked for Sanofi at the time of study, currently at Amgen, Thousand Oaks, California, USA., Zhang B; Sanofi, Global Oncology, Cambridge, Massachusetts, USA., Hopke J; Sanofi, Large Molecule Research, Cambridge, Massachusetts, USA., Deng G; Sanofi, Global Oncology, Cambridge, Massachusetts, USA., Zhu C; Sanofi, Global Oncology, Cambridge, Massachusetts, USA., Macé S; Sanofi, Research and Development, Paris, France., Chiron M; Sanofi, Research and Development, Paris, France., Adrian F; Sanofi, Global Oncology, Cambridge, Massachusetts, USA.; Worked for Sanofi at the time of the study, currently at HiFiBio Therapeutics, Cambridge, Massachusetts, USA., Fukao T; Sanofi, Global Oncology, Cambridge, Massachusetts, USA., Basile FG; Sanofi, Global Oncology, Cambridge, Massachusetts, USA.; Worked for Sanofi at the time of the study, currently at, Nurix Therapeutics, San Francisco, California, USA., Martin T; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.

Publikováno v: Transfusion [Transfusion] 2022 Nov; Vol. 62 (11), pp. 2334-2348. Date of Electronic Publication: 2022 Oct 14.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

Autor: O'Donnell EK; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Laubach JP; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA., Yee AJ; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Mass General/North Shore Cancer Center, Danvers, MA, USA., Chen T; Dana-Farber Cancer Institute, Boston, MA, USA., Huff CA; Johns Hopkins Hospital, Baltimore, MD, USA., Basile FG; Cape Cod Hospital, Hyannis, MA, USA., Wade PM; Cape Cod Hospital, Hyannis, MA, USA., Paba-Prada CE; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA., Ghobrial IM; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA., Schlossman RL; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA., Burke JN; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Harrington CC; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Lively KJ; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Lyons HF; Mass General/North Shore Cancer Center, Danvers, MA, USA., Munshi NC; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA., Anderson KC; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA., Trippa L; Dana-Farber Cancer Institute, Boston, MA, USA., Richardson PG; Harvard Medical School, Boston, MA, USA.; Dana-Farber Cancer Institute, Boston, MA, USA., Raje NS; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2018 Jul; Vol. 182 (2), pp. 222-230. Date of Electronic Publication: 2018 May 08.

Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.

Autor: Basile FG

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2009 Apr; Vol. 50 (4), pp. 653-5.